Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

Andrii Borodai/iStock via Getty Images Alderya – Overview Aldeyra (NASDAQ:ALDX or the Company), is a small cap, development-stage biotech company with a portfolio of RASP (reactive aldehyde species) modulating compounds. The lead drug is a topical therapy for dry eye disease, reproxalap, that recently received a complete response letter (CRL), a rejection from the FDA. The Company believes it has a clear path to provide additional data and obtain approval for reproxalap in early 2025. The Company also h ...